Nautilus Neurosciences, Inc.: Series A $14.5M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Migraine, X - Neurology, X - Pain, XX - NJ

Nautilus Neurosciences (Bridgewater, NJ) near commercial-stage specialty neurology pharma focused on migraine and acute pain, closed a $14.5M Series A financing. Participants include Tailwind Capital.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

Feb

2010

Afferent Pharmaceuticals, Inc.: Series A $23M

Posted in I - Series A, Q - 4Q09, R - WEST, X - Pain, XX - CA

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

SantoSolve, AS: Series C $5.5M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Analgesic, X - Pain

SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oct

2009

Zogenix, Inc.: Series B $36M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, X - Pain, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.

Jul

2009

Limerick BioPharma, Inc.: Series C $15M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Immunology, X - Metabolism, X - Pain, XX - CA

Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.

Jun

2009

Xanodyne Pharmaceuticals, Inc.: Series D $38M

Posted in I - Series D, Q - 2Q09, R - SOUTH EAST, X - Menorrhagia, X - Pain, XX - KY

Xanodyne Pharmaceuticals (Newport, KY) an clinical-stage specialty pharmaceutical company focused on pain and menorrhagia, closed a $38M Series D financing. Participants include MPM Capital, AIG Investments, Aisling Capital, Blue Chip Venture Company, Essex Woodlands Health Ventures, HealthCare Ventures and Union Springs Pharmaceuticals.

Apr

2009

Orthocon, Inc.: Series B $25M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Anesthetic, X - Device (Delivery), X - Device (Hemostat), X - Pain, XX - NJ

Orthocon (North Brunswick, NJ) a preclinical-stage company focused on implantable devices that deliver therapeutics to bone, closed a $25M Series B financing. Participants include ProQuest Investments, Canaan Partners and BB Biotech Ventures.

Mar

2009

Ikano Therapeutics, Inc.: Series B $9M

Posted in I - Series B, Q - 1Q09, R - SOUTH EAST, X - Epilepsy, X - Pain, X - Seizures, XX - KY

Ikano Therapeutics (Lexington, KY) a clinical-stage nasal delivery platform company focused on seizures and pain, closed a $9M Series B financing, the final tranche of a $18M round. Participants include SV Life Sciences, Burrill & Co., Tullis-Dickerson, Fidelity Biosciences, Apjohn Ventures, Fort Washington Capital, Commonwealth Seed Capital and Kentucky Co-Investment Partners.

Jan

2009

Hydra Biosciences, Inc.: Series D $22M

Posted in I - Series D, Q - 1Q09, R - NORTH EAST, X - Inflammation, X - Pain, XX - MA

Hydra Biosciences (Cambridge, MA) a pre-clinical stage developer of therapeutics for pain, inflammation and cardiovascular disease, closed a $22M Series D financing. Participants include MedImmune Ventures, Advanced Technology Ventures, Abingworth, Polaris Venture Partners, BioVenture Investors, Biogen Idec Ventures and Lilly Ventures.

Dec

2008

Spinifex Pharmaceuticals, Ltd.: Series B $12M

Posted in I - Series B, Q - 3Q08, R - INTERNATIONAL, X - Pain

Spinifex Pharmaceuticals (Australia) pain drug development company, closed a $12M Series B financing. Participants include GBS Venture Partners Limited, Brandon Capital Partners and Uniseed.

« Previous Entries

to top of page...